The objective of this study is to evaluate effectiveness and safety of BIOFREEDOM™ FAMILY stent in the "real world" daily practice as compared with other drug-eluting stents.
BIOFREEDOM™ FAMILY stent means that Biofreedom stent, Biofreedom Ultra and the other stents with names starting with Biofreedom.
Study Type
OBSERVATIONAL
Enrollment
218
Percutaneous coronary intervention with BIOFREEDOM™ FAMILY stent
Hallym University Sacred Heart Hospital
Anyang, South Korea
Soonchunhyang University Hospital, Cheonan
Cheonan, South Korea
The Catholic University of Korea, Daejeon ST. Mary's Hospital
Daejeon, South Korea
Chonnam National University Hospital
Gwangju, South Korea
Composite event rate of death, non-fatal myocardial infarction (MI), or Target- Vessel Revascularization (TVR)
Time frame: 1 year
All cause death
Time frame: 5 year
Cardiac death
Time frame: 5 year
Myocardial Infarction
Time frame: 5 year
Composite event rate of death or myocardial infarction (MI)
Time frame: 5 year
Composite event rate of cardiac death or myocardial infarction (MI)
Time frame: 5 year
Target- Vessel Revascularization
Time frame: 5 year
Target- Lesion Revascularization
Time frame: 5 year
Stent thrombosis
Time frame: 5 year
Stroke
Time frame: 5 year
Procedural Success rate
defined as achievement of a final diameter stenosis of \<30% by visual estimation, without the occurrence of death, Q-wave MI, or urgent revascularization during the index hospitalization.
Time frame: 5 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Gachon University Gil Hospital
Incheon, South Korea
Inje University Pusan Paik Hospital
Pusan, South Korea
Asan Medical Center
Seoul, South Korea
Eulji General Hospital
Seoul, South Korea